相关实验视频

Updated: Jun 11, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

林格利普丁对宫癌细胞系的抗增殖作用

Ali Muafaq Said¹, Kawakeb Najim Abdulla², Nihad Hussein Ahmed³

¹Al-Amarah University College, Iraq.

Asian Pacific journal of cancer prevention : APJCP

|September 29, 2024

概括

利纳吉普丁以时间依赖的方式抑制子宫癌细胞的生长. 分子对接表明,利纳利普丁向人体热冲击蛋白90 (Hsp90),表明潜在的抗癌机制.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
分子生物学分子生物学

背景情况:

宫癌仍然是一个重大的全球健康问题.
热冲击蛋白90 (Hsp90) 与癌细胞的增殖和存活有关.
准Hsp90是一种有前途的癌症治疗策略.

研究的目的:

评价林格利普丁在抑制子宫癌细胞增殖方面的疗效.
为了研究林格利普丁作为Hsp90抑制剂的潜力.
探索林格利普丁和Hsp90.0.之间的分子相互作用.

主要方法:

细胞毒性测试是在24小时和72小时对宫癌细胞系 (Hela) 进行的.
使用Biovia发现工作室和AutoDock工具进行了分子对接模拟.
相互作用分析涉及识别绑定站点和计算对接分数.

主要成果:

利纳吉普丁以时间依赖的方式显著抑制了宫癌细胞的增殖.
分子对接揭示了人体Hsp90.90上林格利平的11个潜在结合点.
观察到强大的结合亲和力,总对接得分为-10.3 kcal/mol,与凝胺氨酸相当.

结论:

林格利普丁对宫癌细胞具有时间依赖的细胞毒性作用.
分子对接数据强烈表明,利纳利普丁向人类的Hsp90.
林格利普丁通过抑制Hsp90活性,显示出作为抗癌剂的潜力.

关键词:

宫癌是发生在宫癌的原因之一.整个癌症细胞系是癌症细胞系.化学对接化学对接热冲击蛋白质 90 90 90 90 90 90 90 90 90 热冲击蛋白质是什么?热冲击蛋白质是什么?林纳利普丁 (linagliptin) 的使用情况

更多相关视频

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...